tetano
Editor, Senior Moderator
Infection
. 2022 Feb 18.
doi: 10.1007/s15010-022-01779-x. Online ahead of print.
High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV
Hiroaki Sasaki[SUP] 1 [/SUP], Nobuyuki Miyata[SUP] 2 [/SUP], Yukihiro Yoshimura[SUP] 2 [/SUP], Natsuo Tachikawa[SUP] 2 [/SUP]
Affiliations
Abstract
Purpose: Casirivimab/imdevimab (REGN-COV), a cocktail of neutralizing antibodies against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, was shown to be an effective treatment and post-exposure prophylaxis measure for coronavirus disease 2019 (COVID-19). We assessed the antibody titers among patients who received REGN-COV with the purpose of evaluating this therapeutic and prophylactic option from the serological point of view.
Methods: We collected serological data of patients with COVID-19 who were treated with REGN-COV 1200 mg (casirivimab 600 mg/imdevimab 600 mg). Antibody titers were assessed within 24 h before and within 48 h after the administration of REGN-COV using ARCHITECT SARS-CoV-2 immunoglobulin (Ig)G (IgG[SUB]NC[/SUB]), which is against nucleocapsid protein, and ARCHITECT SARS-CoV-2 IgG II Quant (IgG[SUB]SP[/SUB]), which is against spike protein.
Results: A total of nine patients were evaluated. IgG[SUB]SP[/SUB] was elevated after REGN-COV administration with a median of 208,370 Arbitrary Units/mL while simultaneous IgG[SUB]NC[/SUB] remained low. With the simple linear regression model, the IgG[SUB]SP[/SUB] after the REGN-COV administration was correlated with the reciprocal of ideal body weight.
Conclusion: The high titer of IgG[SUB]SP[/SUB] supports the clinical benefit of therapeutic and prophylactic use of REGN-COV from the serological point of view.
Keywords: Antibody titer; COVID-19; Casirivimab/imdevimab; REGN-COV; SARS-CoV-2.
. 2022 Feb 18.
doi: 10.1007/s15010-022-01779-x. Online ahead of print.
High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV
Hiroaki Sasaki[SUP] 1 [/SUP], Nobuyuki Miyata[SUP] 2 [/SUP], Yukihiro Yoshimura[SUP] 2 [/SUP], Natsuo Tachikawa[SUP] 2 [/SUP]
Affiliations
- PMID: 35181864
- DOI: 10.1007/s15010-022-01779-x
Abstract
Purpose: Casirivimab/imdevimab (REGN-COV), a cocktail of neutralizing antibodies against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, was shown to be an effective treatment and post-exposure prophylaxis measure for coronavirus disease 2019 (COVID-19). We assessed the antibody titers among patients who received REGN-COV with the purpose of evaluating this therapeutic and prophylactic option from the serological point of view.
Methods: We collected serological data of patients with COVID-19 who were treated with REGN-COV 1200 mg (casirivimab 600 mg/imdevimab 600 mg). Antibody titers were assessed within 24 h before and within 48 h after the administration of REGN-COV using ARCHITECT SARS-CoV-2 immunoglobulin (Ig)G (IgG[SUB]NC[/SUB]), which is against nucleocapsid protein, and ARCHITECT SARS-CoV-2 IgG II Quant (IgG[SUB]SP[/SUB]), which is against spike protein.
Results: A total of nine patients were evaluated. IgG[SUB]SP[/SUB] was elevated after REGN-COV administration with a median of 208,370 Arbitrary Units/mL while simultaneous IgG[SUB]NC[/SUB] remained low. With the simple linear regression model, the IgG[SUB]SP[/SUB] after the REGN-COV administration was correlated with the reciprocal of ideal body weight.
Conclusion: The high titer of IgG[SUB]SP[/SUB] supports the clinical benefit of therapeutic and prophylactic use of REGN-COV from the serological point of view.
Keywords: Antibody titer; COVID-19; Casirivimab/imdevimab; REGN-COV; SARS-CoV-2.